These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2358837)

  • 1. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support.
    Dunphy FR; Spitzer G; Buzdar AU; Hortobagyi GN; Horwitz LJ; Yau JC; Spinolo JA; Jagannath S; Holmes F; Wallerstein RO
    J Clin Oncol; 1990 Jul; 8(7):1207-16. PubMed ID: 2358837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support.
    Dunphy FR; Spitzer G; Fornoff JE; Yau JC; Huan SD; Dicke KA; Buzdar AU; Hortobagyi GN
    Cancer; 1994 Apr; 73(8):2157-67. PubMed ID: 8156520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
    Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Sniecinski I
    Cancer; 1994 Jan; 73(1):125-34. PubMed ID: 7903906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study.
    Humblet Y; Symann M; Bosly A; Delaunois L; Francis C; Machiels J; Beauduin M; Doyen C; Weynants P; Longueville J
    J Clin Oncol; 1987 Dec; 5(12):1864-73. PubMed ID: 2824708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
    Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
    Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
    Ayash LJ; Elias A; Schwartz G; Wheeler C; Ibrahim J; Teicher BA; Reich E; Warren D; Lynch C; Richardson P; Schnipper L; Frei E; Antman K
    J Clin Oncol; 1996 Nov; 14(11):2984-92. PubMed ID: 8918496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
    Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
    J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation.
    Ghalie R; Richman CM; Adler SS; Cobleigh MA; Korenblit AD; Manson SD; McLeod BC; Taylor SG; Valentino LA; Wolter J
    J Clin Oncol; 1994 Feb; 12(2):342-6. PubMed ID: 8113841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tandem autotransplantation for the treatment of metastatic breast cancer.
    Broun ER; Sridhara R; Sledge GW; Loesch D; Kneebone PH; Hanna M; Hromas R; Cornetta K; Einhorn LH
    J Clin Oncol; 1995 Aug; 13(8):2050-5. PubMed ID: 7636548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.
    Wallerstein R; Spitzer G; Dunphy F; Huan S; Hortobagyi G; Yau J; Buzdar A; Holmes F; Theriault R; Ewer M
    J Clin Oncol; 1990 Nov; 8(11):1782-8. PubMed ID: 2121909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer.
    Ayash LJ; Wheeler C; Fairclough D; Schwartz G; Reich E; Warren D; Schnipper L; Antman K; Frei E; Elias A
    J Clin Oncol; 1995 Aug; 13(8):2043-9. PubMed ID: 7636547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma.
    Spitzer G; Farha P; Valdivieso M; Dicke K; Zander A; Vellekoop L; Murphy WK; Dhingra HM; Umsawasdi T; Chiuten D
    J Clin Oncol; 1986 Jan; 4(1):4-13. PubMed ID: 3510281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
    Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
    Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation.
    Neidhart JA; Kohler W; Stidley C; Mangalik A; Plauche A; Anderson T; Quenzer RW; Rinehart JJ
    J Clin Oncol; 1990 Oct; 8(10):1728-38. PubMed ID: 2213108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment.
    Klumpp TR; Goldberg SL; Magdalinski AJ; Mangan KF
    Bone Marrow Transplant; 1997 Aug; 20(4):273-81. PubMed ID: 9285541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
    Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
    Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.